Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma

Abstract

To explore the effect of R-CHOP regimen of pegylated liposomal doxorubicin (PLD) on elderly stage Ⅲ-Ⅳ diffuses large B-cell lymphoma (DLBCL). A retrospective analysis was conducted on the treatment information 80 elderly cases of stage III-IV DLBCL admitted to our hospital from April 2017 to April 2020. According to treatment methods, they were divided into experimental groups (40 cases, using R-CHOP with PLD) and controls group (40 cases, using the traditional R-CHOP regimen). We compared the treatment effect, survival rate, cardiotoxicity and adverse reactions of the patients. (1) The short-term degree of effectiveness treatment in the experimental group was 85%, which was not significantly different from 80% in other patients (p>0.05). (2) 2-year OS or PFS of experimental group were better more (p<0.01) and the treatment advantage of the experimental group increased with time. (3) Incidence of neutropenia and alopecia in experimental group was lower more (p<0.05). (4) Cardiotoxicity indexes of experimental group were lower (p<0.05). The PLD-containing R-CHOP regimen can improve the long-term inventory level elderly cases of stage III-IV DLBCL, reduce the incidence of grade IV neutropenia and alopecia, alleviate the cardiotoxicity caused by chemotherapy, and have better safety.